Background: Iron deficiency anemia is one of the most prevalent types of nutritional disorder in the world. Its etiology is multifaceted and it generally results when the iron demands of the body are not met by iron absorption. Iron deficiency anemia can be symptomatically compared with Pandu Roga in Ayurveda.
INTRODUCTION
Iron deficiency anemia is the most common type of nutritional disorder in the world. The prevalence of anemia in India among women and children is highest in the world. In India, the prevalence of anemia is high because of 1 :
• Low dietary intake, specifically poor iron (less than 20 mg/day) and folic acid intake (less than 70 mg/day); • Poor bioavailability of iron (3-4% only) in phytate fiber-rich vegetarian diet; and • Chronic blood loss due to infection, such as malaria, and parasitic infestations, such as hookworm.
Anemia is a state of reduced hemoglobin in the body. It is associated with various signs and symptoms like breathlessness, pallor, fatigue, weakness, etc. Patients report fatigue and exercise-associated dyspnea besides paleness of the skin. As per Ayurveda, we may correlate this with Pandu based on signs and symptoms of the disease.
2
Iron is present in the body abundantly in the form of hemoglobin and in the form of ferritin that helps in erythropoiesis, besides other forms of proteins that have iron in them. A serum ferritin level of 15 μg/L or less is diagnostic of iron deficiency. Red blood cell (RBC) size, color, mean corpuscular volume, and packed cell volume are the other parameters that can be assessed to diagnose and evaluate the effect of treatment. 3 Pandu in Ayurveda is characterized with a marked vitiation of Pitta along with the other doshas. Due to specific nidana (etiological factors), vitiated vata displaces Pitta which vitiate further Kapha, rasa, rakta, and mamsa, gets lodged in between twak and mamsa resulting in yellowish or greenish discoloration of the skin. The pro dromal symptoms include palpitation, dryness of the skin, absence of sweating, and tiredness of the body which are vata predominant. When the disease manifests properly, the symptoms exhibited include low digestive activity and anorexia which reflect the impairment of agni due to vitiation of Pitta. The symptoms like tinnitus, tiredness even after small exertion, body ache, low voice, brittle hair, etc., can be attributed to Vata and the symptoms like swelling of eye sockets, drowsiness, frequent spitting, etc., due to Kapha. Therefore, management of the disease should be aimed at correcting the vitiation of Tridosha and improving the Agni.
Punarnavadi Mandura was selected as it is an iron preparation being used since years to treat Pandu roga and as Rukshata is one of the four prodromal symptoms of Pandu, Dadimadi Ghrita was selected for Abhyantar Snehana. Further, Dadimadi Ghrita was also used to counter the Khaributata of body tissue or Dhatus. Dadimadi Ghrita is also responsible for Agni deepan and thus was used so that Punarnavadi Mandura can be better absorbed.
OBJECTIVES
To evaluate the efficacy and safety of two classical Ayurvedic formulations Punarnavadi Mandura and Dadimadi Ghrita in patients with iron deficiency anemia.
MATERIALS AND METHODS

Study Design
The study was a prospective open-label multicenter trial executed at three peripheral centers of the Central Council for Research in Ayurvedic Sciences, Ministry of AYUSH. The study was approved by the Institutional Ethics Committee of all the three participating centers and was done in accordance with the World Health Organization Good Clinical Practice Guidelines. The clinical trial has also been registered in the Clinical Trial Registry of India (CTRI/2012/03/002524).
Study Participants
A total of 150 participants were to be enrolled in the trial, 50 from each of the three centers, viz., Central Ayurveda Research Institute for Respiratory Disorders, Patiala, M.S.
Regional Ayurveda Research Institute for Endocrine Disorders, Jaipur, and Central Ayurveda Research Institute for Hepatobiliary Disorders, Bhubaneswar. Patients were screened in accordance with the inclusion and exclusion criteria mentioned in the protocol. A total of 103 patients following the screening criteria were recruited in the study after obtaining written informed consent.
Inclusion Criteria
Patients of either sex aged between 15 and 60 years, with hemoglobin ranging from 8 gm% to 10 gm% and who were willing to participate in the study for 14 weeks.
Exclusion Criteria
Patients suffering from thalassemia major, aplastic anemia, or sickle cell anemia were excluded from the study. Moreover, patients with evidence of malignancy, patients suffering from any other major systemic illness necessitating long-term therapy, patients with past history of atrial fibrillation, coronary artery disease, acute coronary syndrome, myocardial infection, stroke, or severe arrhythmia in the last 6 months were also excluded. Further, symptomatic patients with clinical evidence of heart failure, patients with poorly controlled hypertension defined as systolic blood pressure of >160 mm Hg and diastolic blood pressure of >100 mm Hg were also excluded. Patients with blood sugar fasting level of >250 mg/dL also fell in our exclusion range.
Patients on prolonged (≥6 weeks) medication with corticosteroids, antidepressants, anticholinergics were excluded from the study to safeguard the outcomes of the study medications. Patients with concurrent serious hepatic disorder defined as aspartate aminotransferase and/or alanine aminotransferase, total bilirubin, alkaline phosphatase >2 times the upper normal limit, or renal disorders defined as serum creatinine >1.2 mg/dL, total serum cholesterol and/or serum triglycerides >250 mg/dL, severe pulmonary dysfunction, uncontrolled bronchial asthma, and/or chronic obstructive pulmonary disease were also excluded. Alcoholics or drug abusers, pregnant and lactating women, and patients who have the past record of hypersensitivity to any of the ingredients of trial medications were also excluded. Patients who have participated in any other clinical trial during the past 6 months were also excluded from the study.
Study Interventions
The study medications included Punarnavadi Mandura 4 in the dose of 500 mg (two tablets of 250 mg) twice daily given with water for a period of 12 weeks and Dadimadi Ghrita 5 in a dose of 10 gm twice daily given orally before food, with lukewarm water. Both the Ayurvedic formulations were procured from Good Manufacturing Practice-certified Ayurvedic Pharmaceutical industries and standardized following the standard laid in Ayurvedic Pharmacopoeia of India. Deworming was done only in the patients who had worm infestation.
Patients were also guided regarding pathya-apathya and about iron-rich food items.
Study Procedure
On the enrolment day at baseline (visit 1), patient's demographic profile, medical history, family history particularly related to iron deficiency anemia, sharirik prakriti, and vital parameters were recorded. Subsequent visits were planned at an interval of 2 weeks [14th day (visit 2), 28th day (visit 3), 42nd day (visit 4), 56th day (visit 5), 70th day (visit 6), and 84th day (visit 7)]. Patients were assessed and given study medications at each subsequent visit till 84th day. There was also a without medication follow-up after 2 weeks of 84th day visit. Details of clinical assessment and study schedule are given in Flow Chart 1.
At the study site, data of all the patients were recorded in predesigned case report forms (CRFs) and was also entered in electronic formats (e-formats) designed in MSExcel with many data validation checks to ensure correct data entry. The e-formats and xerox of the CRFs along with the laboratory investigation reports of the patients were sent by the participating centers to the Council's headquarters on a weekly basis for the purpose of clinical trial monitoring.
Out of the total 103 patients enrolled in the study, 38 dropped out during the course of the study. Intentionto-treat analysis was done, and the data of all those patients who have completed at least 14th day visit were imputed by last observation carried forward method (LOCF). Patients who dropped out after baseline visit only were excluded from analysis. Hence, data of a total 90 patients were used for statistical analysis. Flow Chart 2 shows the outflow of the patients in the study.
Outcomes
Primary outcome measure was mean change in hemoglobin level at 84th day from baseline. The secondary outcome measures was mean change in serum ferritin level, change in peripheral blood smear, and relief in symptoms like weakness, fatigue, dizziness, headache, palpitation, shortness of breath, irritability, taste disturbances, pallor, brittle nails, pica, glossitis, angular stomatitis, and ringing in the ears at 84th day as compared with baseline.
Statistical Analysis
Primary outcome and secondary outcome measures, i.e., hemoglobin and serum ferritin, were analyzed as mean change in the response from baseline to 84th day by 
RESULTS
Data of a total 90 patients (8 males and 82 females) were
used for statistical analysis. Out of these, maximum patients [31 (34.4%)] were in the age group of 15 to 25 years. Table 1 shows the demographic profile of the patients. Fifty-five (61.1%) patients were of Vataja-pittaja sharirik prakriti. Vital parameters of the patients recorded at baseline of the patients are shown in Table 2 . Mean systolic blood pressure was 112.47 mm Hg and mean diastolic blood pressure was 70.76 mm Hg.
It was also observed from the data that 60 (66.7%) of the patients were married; 71 (78.9%) of the patients were literate enough to read and write. Maximum number of patients [46 (51.1%)] were housewives and were involved in domestic work which included physical labor also.
Maximum numbers of patients were residing in urban area
It was also noticed that 55 (61.1%) patients were vegetarians, addiction of any kind was not found in 95.6% of cases, while smoking and chewing tobacco were observed in 2.2% of cases each; 97.8% of the cases were nonalcoholic and 2.2% had the habit of taking alcohol occasionally.
Significant effect of Punarnavadi Mandura and Dadimadi Ghrita was also seen on the common complaints faced by patients suffering from iron deficiency anemia. The complaint of weakness was observed in 89 patients at baseline, which reduced by 25%, and was found only in 66 patients at the end of treatment. Complaint of fatigue reduced in 43.8% patients and dizziness reduced in 68.5% patients. A significant reduction was also seen in the complaint of headache, which reduced in 75.08% patients. The effect of the trial medications Punarnavadi Mandura and Dadimadi Ghrita on other complaints faced by patients of iron deficiency anemia is shown in Table 3 .
Effect of the study medications was also assessed by paired t-test on hematological parameters compared at baseline and at 84th day. Table 4 shows the results of the analysis on hematological parameters. Mean hemo globin (g/dL) level increased from a baseline value of 9.29 to 9.40 at 84th day, which was, however, not statistically significant. A significant increase in mean serum iron (μg/dL) level (p = 0.005) was also seen, which rose from baseline value of 41.13 to 50.02 at the end of the treatment period (Graph 1).
Flow Chart 2:
Outflow of the patients in the study 
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Safety Profile
The effect of this treatment on various safety parameters, such as liver function tests and renal function tests, was assessed on baseline and at 84th day visit. The values were within limits during the entire trial period (Graphs 2 to 4). Table 5 shows the effect of the drugs on the safety parameters
DISCUSSION AND CONCLUSION
Iron deficiency anemia is very common in Indian population. The causes are nutritional deficiency, reduced bioavailability of iron, and chronic blood loss due to one or the other reason. Ayurveda is the oldest recorded medical science and it has dealt with anemia as Pandu It was noticed from the data that maximum number of patients were females. This may be due to the fact that the iron loss in the form of monthly menstruations, pregnancies, and lactation is rampant in females of reproductive age.
Further, it was also noteworthy that the levels of serum iron increased significantly in the study, with a decrease in serum ferritin levels, which suggests that the total iron content of Punarnavadi Mandura and Dadimadi Ghrita is comparable with conventional iron therapies.
Significant decrease in serum ferritin and decrease in total iron-binding capacity suggest that sufficient Values are expressed as mean (standard deviation), $ Compared using paired t-test at baseline and 84th day; *p-value <0.05 has been considered as significant; SGOT: Serum glutamic oxalocetic transaminase; SGPT: Serum glutamic pyruvic transaminase amount of iron is present in serum, which is required for formation of RBCs. However, hemoglobin level has not increased markedly in the study, which may be due to shorter intervention period. The life of RBCs is 120 days; hence, in the future, long-term studies with larger sample size may be taken up to further validate the efficacy of these interventions. 
